# Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia

> **NCT05929248** · PHASE2 · UNKNOWN · sponsor: **Guanmin Gao** · enrollment: 64 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **DRUG:** Telitacicept
- **DRUG:** conventional therapy
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05929248
- **Lead sponsor:** Guanmin Gao
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-01
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 64 (ESTIMATED)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05929248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05929248, "Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05929248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*